Drugmaker Eli Lilly says it is expanding access to its experimental weight loss drug retatrutide, which has not yet been approved by the FDA. The company says obese patients taking the drug in clinical trials lost between 73 and 85 pounds over two years. Dr. Rachel Pessah Pollack discusses what is known about its safety — and who is eligible for the medication. #weightloss #health #retatrutide #glp1